Grünecker Patent- und Rechtsanwälte PartG mbB: Informationen

Am 23. März 2023 hat die Große Beschwerdekammer des Europäischen Patentamts ihre Entscheidung in der Sache G2/21 über die Zulässigkeit nachveröffentlichter Beweismittel/Daten, die zur Unterstützung einer erfinderischen Tätigkeit herangezogen werden.

Steven M. Zeman analysiert die Entscheidung und fasst die wichtigsten Erkenntnisse zusammen.

Bitte...

Geteiltes Wissen ist doppeltes Wissen

Wir teilen uns gerne mit – und freuen uns auf Ihr Feedback.

G 2/21: EPO Enlarged Board of Appeal Rules on Admissibility of Post-Published Evidence in Support of Inventive Step

Kapitel in dem neuen Buch "WINNING WITH IP: MANAGING INTELLECTUAL PROPERTY TODAY"

5 Considerations In Preparing For EU's New Patent System

Media and Entertainment Law Review

Media and Entertainment Law Review

IP und der Austritt Großbritanniens aus der EU

The plausibility battleground at the EPO

The CJEU installs another hurdle for SPCs on functionally defined products and ends second medical use SPCs

Remdesivir und Corona: Zwangslizenz als Mittel zum Zweck?

Media and Entertainment Law Review - Germany

UPC – Ratification Process not affected by Brexit

BREXIT

Can diagnostic data be protected as “direct product” of a process?

Pay-for-delay: Play by the rules

Brexit Consequences for Patent Litigation

Succession in title and priority entitlement in the European Patent Office

Devising an international patent litigation strategy

Pressemeldung Auto-Patentindex 2015

FRAND-RULES CLEARER AFTER CJEU RULED ON HUAWEI V. ZTE

PLANT PATENTS IN EUROPE

IAM Yearbook 2015

Advocate General of the CJEU: Stem cells from parthenotes are patentable

Recent Decisions of the European Court of Justice of the European Union on SPCs: A few Answers – Many Questions

Ein Jahr nach der EuGH-Vorlage des Landgerichts Düsseldorf zu FRAND - Was ist passiert?

Informationen für Markeninhaber zum Schutz ihrer Marken im Zuge der Einführung der neuen Top Level Domainnamen (gTLD)

FRAND-based litigation and competition issues in Europe

Red Soles Aren’t Made for Walking: A Comparative Study of European Fashion Laws

Update zum FRAND-Einwand - Landgericht Düsseldorf legt Fragen zu den grundsätzlichen Voraussetzungen des FRAND -Einwands dem EuGH vor

EU-Kommission äußert sich zum FRAND-Einwand

Nach 30 Jahren: Endlich ein echtes einheitliches Europäisches Patent

Patents and Standards: Recent Developments in Germany

When is a process for the production of plants “essentially biological”? Decisions of the Enlarged Board of Appeal (G1/08 and G2/07)

The EPO Enlarged Board of Appeal decides on dosage regimens (G2/08) and treatment by surgery (G1/07)

Will the European Patent Court ever become reality?

Enhanced Patent System in Europe

Enforcing Patents in Germany

Die große Beschwerdekammer des EPA entscheidet über chirurgische Verfahren G 1/07, Treatment by surgery / MEDI-PHYSICS

When Patents Become Standard: Litigation for ‘Essential’ Patents

Enforcing IP Rights in the EU

Patentees beware German antitrust rules

The EPO’s Decision G 2/06 on the Patentability of Human Embryonic Stem Cells: Sounding the Bell for the Next Round?

Cross-border: Europe - Implementation of the EU IP Rights Enforcement Directive

The London Agreement – Implementation in Germany

The Olanzapine Patent Dispute: German court grants a preliminary injunction on a patent invalidated by the first instance Federal Patent Court

Chemical Selection Inventions in the EPO and in Germany: Continued Divergence in Legal Interpretation

The ever-expanding extraterritorial reach of patents

Community Design Applications under the Hague Agreement

Navigating the European litigation maze

Applicant-friendliness of the EPO for second medical use claims: A mixed blessing

Does T 0866/01 (“Euthanasia Compositions”) of an Appeal Board of the EPO provide the Answers for the Enlarged Board of Appeal Case G2/06 (“Primate Embryonic Stem Cells”)?

The Enforceability of Medical Use Claims in Germany

Questions and Answers relating to Divisional Applications at the EPO

Patentability of Diagnostic Methods under the EPC: A new Referral to the Enlarged Board of Appeal by the President of the EPO

Act implementing the Directive on the legal protection of biotechnological inventions in Germany (BioPatG)

Markenbewertung und Markenverwertung

What makes a Co-Worker a Co-Inventor?

Patentability of Diagnostic Methods Under the Most Recent Decision of the Enlarged Board of Appeal G 1/04PDF

Patentability of Diagnostic Methods Under the Most Recent Decision of the Enlarged Board of Appeal G 1/04PDF

New Rules on Technology Licensing

Community Designs - Infringement and Invalidity Decisions

Restoration of Disclaimer Practice at the EPO

The Immoral Gene: Does it really exist?

Decisive Steps Towards The Community Patent

Patenting of Stem Cells and Processes involving Stem Cells according to the Rules of the European Patent Conventio

Registered and Unregistered European Community Designs

Practical Aspects of Registered European Community Designs

Recent Case Law of the EPO regarding Software/Business method-related Inventions

Patentability of stem cells in view of the European group of Ethics

Design Protection in the European Union

Standard for Valid Priority Claim Defined by EPO Enlarged Board of Appeal

Time frame for costs of patent ligitation in Germany

Method of Treatment Inventions under the EPC: What kind of Protection can you get?

Are business methods patentable in Europe?

Parallel Import subject to Customs Seizure

New Rules of the European Patent Office for Biotechnological Inventions

Are Expressed Sequence Tags Patentable under the European Patent Convention?

The Protection of Technical Innovations and Designs in Germany

Outline of the Preliminary Injunction Procedure in Intellectual Property Matters in GermanyPDF

Geteiltes Wissen
ist doppeltes Wissen